MAPT and Alzheimer disease: Geldanamycin has been effective in several preclinical studies of Alzheimer’s disease, showing the ability to suppress memory deficits in β-amyloid-injected rats [125] and induce the degradation of misfolded tau protein [126] and has also been shown to reduce brain injury in a mouse model of intracerebral hemorrhage and improve the neurological outcome of these mice [127].